Paratus New Normal TCB Private Investment drastically reduces stake from 6.81% to 2.91% via CB conversion and on-market sale... simple investment purpose sale raises downside pressure on stock price

Existing major shareholder Paratus New Normal TCB Private Investment (affiliated with Paratus Investment) significantly reduced its stake in Genome & Company from 6.81% to 2.91%, a decrease of 3.90 percentage points.
The reduction was caused by converting 1,395,065 convertible bonds (conversion price 3,025 won) into common shares and then selling all converted shares on the market (average price approx. 5,805 won).
Related party Paratus Innovation Growth M&A Private Investment also converted and sold 597,821 CB shares, further reducing the overall stake.
Although the filer states the purpose as 'simple investment', the massive sell-off in a short period may pressure stock supply and demand.
The filer's voting rights ratio decreased from 3.23% to 2.65%, partly due to an increase in total outstanding shares (approx. 11.32 million shares).
[AI Comprehensive Analysis]This disclosure indicates that a former major shareholder has largely liquidated its position to realize profits from convertible bonds. The resulting increase in short-term sellable shares could weigh on the stock price. Additionally, the dilution effect from the increased share count should not be overlooked, warranting investor caution.